EBV‑Driven Lymphomagenesis and Management of Chronic Active EBV Infection

Mechanisms of EBV‑Induced Lymphoproliferation

EBV infects and immortalizes host lymphocytes (B‑cells, T‑cells, or NK‑cells) by establishing latency; the infected cell lineage determines disease behavior and prognosis. 1
Latent EBV proteins (EBNA, LMP‑1) drive proliferative signaling and can be demonstrated by immunohistochemistry in tissue specimens. 2
Infection of T‑cells or NK‑cells is associated with a markedly worse prognosis than B‑cell infection and confers a higher risk of progression to aggressive extranodal NK/T‑cell lymphoma or T‑cell lymphoproliferative disease. 2

Chronic urticaria‑like eruptions in chronic active EBV infection represent direct viral cutaneous involvement or systemic inflammatory response rather than simple allergy. 1
Characteristic skin lesions include hydroa vacciniforme‑like eruptions, recurrent necrotic papules that heal with depressed scars, mucocutaneous ulcers, and hypersensitivity to mosquito bites. 2
The classic systemic triad comprises persistent/recurrent fever, lymphadenopathy, and hepatosplenomegaly. 2

Quantitative EBV PCR on peripheral blood mononuclear cells is the gold‑standard laboratory test; viral loads exceeding 10^2.5 copies/mg DNA (≈10 000 IU/mL in whole blood) confirm chronic active EBV infection. [1][2]
A serologic pattern of very high VCA‑IgG (≥1:640), elevated EA‑D‑IgG (≥1:160), and positive EBNA‑1‑IgG indicates active viral replication rather than latent carriage. [1][2]
Skin (or other tissue) biopsy with EBER in‑situ hybridization, EBNA/LMP immunohistochemistry, and T‑cell receptor (or immunoglobulin) gene rearrangement studies provides definitive histopathologic confirmation and distinguishes clonal from reactive proliferations. [1][2]
Double‑staining combining EBER with lineage markers (CD3/CD4/CD8 for T‑cells, CD56 for NK‑cells, CD20 for B‑cells) is essential because T/NK‑cell infection predicts aggressive disease. 2
Flow cytometry typically reveals increased large granular lymphocytes (CD16⁺, CD56⁺, HLA‑DR⁺) and/or activated T‑cells (CD4⁺ or CD8⁺ with HLA‑DR expression). 1

Chronic active EBV infection carries a substantial risk of transformation to T‑cell or NK‑cell lymphoproliferative disorders, especially extranodal NK/T‑cell lymphoma. [1][2]
Hemophagocytic lymphohistiocytosis (HLH) may develop; screening includes ferritin, triglycerides, fibrinogen, and soluble IL‑2 receptor levels. 1
Cardiovascular complications such as coronary artery aneurysms have been reported in affected patients. 1

Isolated treatment of cutaneous manifestations (e.g., urticaria) without addressing the underlying EBV infection does not resolve systemic disease. 1
Allogeneic hematopoietic stem cell transplantation (allo‑HSCT) is the only curative approach for eradicating EBV‑infected T or NK cells; active disease at the time of transplant (fever, liver dysfunction, progressive skin lesions, vasculitis, uveitis) predicts poorer outcomes. (Evidence level not specified in source)
EBV‑specific cytotoxic T‑lymphocytes (CTLs) have demonstrated high efficacy in controlling expansion of EBV‑infected cells, although their availability is limited. [3][4]
Conventional chemotherapy alone is ineffective and may worsen prognosis by inducing immunosuppression and facilitating further viral replication. (Evidence level not specified in source)